Retevmo® (selpercatinib) program presented by Dr. Bryan McIver
This program is sponsored by and the speaker is presenting on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
Retevmo® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
© Lilly USA, LLC 2020. All rights reserved.
Join us to review the clinical data for LIBRETTO-001, examine the efficacy and safety profiles, and explore the dosing, dose modifications, administration, and appropriate testing methods for a biomarker-driven therapy. This program aims to help you identify patients who may be eligible for this treatment option.